HomeAI · summaries
Storia in 7 fonti
FDA approves AstraZeneca’s new kind of hypertension drug
Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” that should ultimately generate $5 billion or more in annual sales.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
healio.com
Baxfendy approved for uncontrolled hypertension
AstraZeneca announced the FDA approved baxdrostat for uncontrolled hypertension as add-on therapy on top of standard care.Baxdrostat (Baxfendy) is the first aldosterone synthase…
- ·
astrazeneca.com
Baxfendy approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension
AstraZeneca’s Baxfendy (baxdrostat) has been approved in the US as a first-in-class aldosterone synthase inhibitor (ASI) for the treatment of hypertension in combination with…
- ·
biopharmadive.com
FDA approves AstraZeneca’s new kind of hypertension drug
Baxfendy inhibits a blood-pressure-raising enzyme and, according to AstraZeneca executives, is poised to be a “big product” that should ultimately generate $5 billion or more in…
- ·
endpoints.news
AstraZeneca's blood pressure pill approved, but competition could be around the corner
One of the key products underpinning AstraZeneca’s goal of hitting $80 billion in revenue by 2030 has been approved by the FDA, the drugmaker said Monday.
- ·
morningstar.com
BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension
BAXFENDY approved in the US as the first and only aldosterone synthase inhibitor treatment for adults with hypertension
- ·
medpagetoday.com
FDA Greenlights Novel Hypertension Pill for Tough-to-Treat Patients
Aldosterone synthase inhibitor baxdrostat indicated as add-on to other antihypertensives
- ·
fiercepharma.com
AstraZeneca notches key FDA nod in hypertension, with an approval sweetener for Fasenra too
After an impressive phase 3 showing last fall, AstraZeneca’s wager on CinCor Pharma and its aldosterone synthase inhibitor (ASI) baxdrostat has continued to pay off. | After an…